Frédéric Rieux Laucat
Inserm Research Director
Imagine Institute (Inserm/AP-HP/Université de Paris)
© Adobe Stock
© Adobe Stock
In very rare cases, children having contracted COVID-19 go on to develop severe inflammation 4 to 6 weeks after infection with SARS-CoV-2. In two-thirds of them, this inflammatory syndrome affects the heart, leading to myocarditis. In a study published in the journal MED, researchers, doctors and teacher-researchers from Inserm, the Paris hospitals group AP-HP and Université de Paris at the Imagine Institute, in collaboration with Institut Pasteur, analyzed blood samples from a cohort of 56 pediatric patients admitted to Hôpital Necker Enfants-Malades AP-HP. What they saw was the abnormal expression of several genes associated with the development of severe forms of myocarditis. A molecular signature that could ultimately help identify those children at risk of developing this rare cardiac inflammation.
Certain children with SARS-CoV-2 develop severe inflammation four to six weeks after infection, with varying symptoms: fever, stomach pain, skin rashes, etc. In around 70% of cases, this so-called “multisystem” inflammatory syndrome affects the myocardium, the muscle responsible for heart contractions. These severe cases of myocarditis were first reported in the UK, in March 2020, before being observed in Italy, France, and then all over the world. What is the explanation behind these rare forms?
In a study published in MED – a journal from Cell Press –, conducted by Inserm researchers Frédéric Rieux-Laucat and Mickaël Ménager (*) working in two laboratories at the Imagine Institute (Inserm, Université de Paris, Paris hospitals group AP-HP), in collaboration with doctors from Hôpital Necker-Enfants Malades AP-HP and Institut Pasteur, cutting-edge molecular investigations were conducted in order to find out more. The result of these investigations was the identification of several genes linked to the development of severe forms of myocarditis in these children.
As part of the study, the authors analyzed blood samples from 56 children hospitalized between April 6 and May 30, 2020. A total of 30 had developed multisystem inflammatory syndrome following SARS-CoV-2 infection, 21 of whom with a severe form of myocarditis, and 9 without. “To understand the difference between these two patient groups, we did several analyses using state-of-the-art techniques: an ultra-sensitive assay of cytokines – the immune system hormones that enable an appropriate response in case of infection –, characterization of blood cell composition, and a cell-by-cell analysis of gene expression“, explains Ménager.
Three molecular abnormalities
In both groups, the researchers found reduced numbers of monocytes and dendritic cells (white blood cells), increased inflammatory cytokine levels, and an overactivation of the so-called “NF-kB pathway” within these cells.
Following closer comparison of the dendritic cells and monocytes of the two groups, the authors observed three specific anomalies in patients with myocarditis: lack of inhibition in the NF-kB pathway, overproduction of “TNF-α” (cytokine involved in NF-kB pathway activation), and finally a lack of response to type I and II interferons (cytokines involved in regulating inflammation).
All of these abnormalities can be explained by the abnormal expression of certain genes. In order to identify these genes, the authors carried out a cell-by-cell genetic analysis.
“Like this we were able to identify and validate over one hundred genes overexpressed specifically in the monocytes and dendritic cells of patients with severe forms of myocarditis“, explains Ménager. A molecular signature that could ultimately enable the development of tests to identify patients at risk of developing this severe cardiac inflammation.
(*) Frédéric Rieux-Laucat heads up the Immunogenetics of Pediatric Autoimmune Diseases laboratory. Mickaël Ménager heads up the Inflammatory Responses and Transcriptomic Networks in Diseases laboratory and the LabTech Single-Cell@Imagine, a platform dedicated to the cell-by-cell study of gene expression.
La cohorte ANRS COV-POPART – « cohorte vaccinale Covid-19 des populations particulières » – a été conçue pour évaluer la réponse immunitaire induite par les vaccins contre la Covid-19 au sein de différents groupes de personnes suivies pour une maladie chronique comparativement ...
The Discovery trial was originally launched in March 2020 by Inserm to evaluate possible treatments for Covid-19. On January 13th, 2021, the Discovery Europe trial Data Safety Monitoring Boards (DSMB) evaluated an interim report based on 776 patients of whom 389 received ...
A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis
C. de Cevins et al.
MED, septembre 2021